CA3150423A1 - Utilisation de l'anticorps anti-p-selectine crizanlizumab pour le traitement de la drepanocytose et de la nephropathie chronique associee a la drepanocytose - Google Patents

Utilisation de l'anticorps anti-p-selectine crizanlizumab pour le traitement de la drepanocytose et de la nephropathie chronique associee a la drepanocytose Download PDF

Info

Publication number
CA3150423A1
CA3150423A1 CA3150423A CA3150423A CA3150423A1 CA 3150423 A1 CA3150423 A1 CA 3150423A1 CA 3150423 A CA3150423 A CA 3150423A CA 3150423 A CA3150423 A CA 3150423A CA 3150423 A1 CA3150423 A1 CA 3150423A1
Authority
CA
Canada
Prior art keywords
antibody
seq
selectin
crizanlizumab
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3150423A
Other languages
English (en)
Inventor
Kenneth ATAGA
Laurie DEBONNETT
Vimal DEREBAIL
Guangyang HAN
Adlette INATI
Julie KANTER
Jeffrey LEBENSBURGER
Santosh SARAF
Claire SHARPE
Pablo BARTOLUCCI
Miona STANKOVIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CA3150423A1 publication Critical patent/CA3150423A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé de traitement d'une maladie rénale chronique due à la drépanocytose chez un patient nécessitant un tel traitement, comprenant l'administration d'une quantité pharmaceutiquement efficace d'un anticorps anti-P-sélectine ou d'un fragment de liaison de celui-ci audit patient et des modes de réalisation de l'invention associés (utilisations, des procédés, des préparations pharmaceutiques et leur utilisation dans la préparation de préparations pharmaceutiques).
CA3150423A 2019-08-08 2020-08-06 Utilisation de l'anticorps anti-p-selectine crizanlizumab pour le traitement de la drepanocytose et de la nephropathie chronique associee a la drepanocytose Pending CA3150423A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962884313P 2019-08-08 2019-08-08
US62/884,313 2019-08-08
PCT/IB2020/057438 WO2021024220A1 (fr) 2019-08-08 2020-08-06 Utilisation de l'anticorps anti-p-sélectine crizanlizumab pour le traitement de la drépanocytose et de la néphropathie chronique associée à la drépanocytose

Publications (1)

Publication Number Publication Date
CA3150423A1 true CA3150423A1 (fr) 2021-02-11

Family

ID=72039639

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3150423A Pending CA3150423A1 (fr) 2019-08-08 2020-08-06 Utilisation de l'anticorps anti-p-selectine crizanlizumab pour le traitement de la drepanocytose et de la nephropathie chronique associee a la drepanocytose

Country Status (6)

Country Link
US (1) US20220324983A1 (fr)
EP (1) EP4010019A1 (fr)
AU (1) AU2020326490A1 (fr)
BR (1) BR112022002282A2 (fr)
CA (1) CA3150423A1 (fr)
WO (1) WO2021024220A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021956A1 (fr) 1992-05-05 1993-11-11 Cytel Corporation Anticorps contre la p-selectine et leurs emplois
WO1994025067A1 (fr) 1993-05-04 1994-11-10 Cytel Corporation Anticorps diriges contre la selectine p et leurs utilisations
RU2368622C2 (ru) 2004-04-13 2009-09-27 Ф.Хоффманн-Ля Рош Аг Антитела к р-селектину
JOP20190101A1 (ar) * 2016-11-03 2019-05-05 Novartis Ag أنظمة علاج
WO2019025847A1 (fr) * 2017-08-04 2019-02-07 Novartis Ag Schémas de traitement

Also Published As

Publication number Publication date
BR112022002282A2 (pt) 2022-07-19
US20220324983A1 (en) 2022-10-13
AU2020326490A1 (en) 2022-03-24
EP4010019A1 (fr) 2022-06-15
WO2021024220A1 (fr) 2021-02-11

Similar Documents

Publication Publication Date Title
AU2007328435B2 (en) Methods of treating hemolytic anemia
US20170306050A1 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
JP2021020909A (ja) がんの治療のための方法、組成物、及びキット
IL292302A (en) Use of glutamate modulating factors in cancer immunotherapy
JP7404230B2 (ja) ネトーシスおよび好中球活性化を処置するための方法
KR20070009996A (ko) 용혈성 질환을 치료하는 방법
CN117695387A (zh) 用于确定和实现抗cd47药剂治疗癌症的治疗有效剂量的方法
AU2018345625A1 (en) Dosage and administration of anti-C5 antibodies for treatment of patients with Membranoproliferative glomerulonephritis
US20150266967A1 (en) Superior efficacy of cd37 antibodies in cll blood samples
JP2022512967A (ja) 抗ＦｃＲｎ抗体を用いたグレーブス眼症の治療方法
WO2018005967A1 (fr) Compositions destinées au traitement de l'amylose
US20240209097A1 (en) Treatment regimens
TW202400637A (zh) April之抗體分子及其用途
US20180244750A1 (en) Methods for treatment of cancer
TW202216195A (zh) April抗體分子及其用途
CA3150423A1 (fr) Utilisation de l'anticorps anti-p-selectine crizanlizumab pour le traitement de la drepanocytose et de la nephropathie chronique associee a la drepanocytose
AU2021330883A9 (en) Use of an anti-pd-1 antibody and a cytotoxic anticancer drug in treatment of non-small cell lung cancer
US20220195061A1 (en) Anti-cd40 antibodies for use in treatment of tidm and insulitis
WO2022076452A1 (fr) Polythérapie pour maladie rénale d'alport
Rovin et al. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody–Positive Primary Membranous Nephropathy
US20170369551A1 (en) METHODS OF TREATING IgA NEPHROPATHY AND HENOCH-SCHONLEIN PURPURA NEPHRITIS USING A B-CELL ACTIVATING FACTOR (BAFF) INHIBITOR
TW202404639A (zh) Aiha之治療
Bruchfeld et al. Rituximab for multirelapsing, steroid-dependent or steroid-resistant, minimal-change nephropathy–a report of nine adult cases
AU2013206217A1 (en) Methods of treating hemolytic anemia